Citigroup Inc Hille Vax, Inc. Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
A detailed history of Citigroup Inc transactions in Hille Vax, Inc. stock. As of the latest transaction made, Citigroup Inc holds 23,471 shares of HLVX stock, worth $44,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,471
Previous 7,033
233.73%
Holding current value
$44,360
Previous $101,000
59.41%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HLVX
# of Institutions
78Shares Held
36.3MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$20.1 Million1.01% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$9.3 Million0.74% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.95 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.7 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.56 Million0.06% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $63.2M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.